A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Clinical trial NCT07541079 · RECRUITING

Trial details

NCT number: NCT07541079
Sponsor: Genentech, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Early Breast Cancer

Start date: 2026-08-15
Primary completion: 2032-06-30
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.